TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32586361
Drug: Bilateral TQL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral TQL block with 30 ml ropivacaine 0.375% each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (TQL group, n=75)
Study: 32586361
Drug: Bilateral TQL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral TQL block with 30 ml saline each on both sides plus postoperative patient-controlled intravenous analgesia with morphine (placebo group, n=75)
Study: 33583740
Drug: Amoxicillin administered
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin administered 24 hours pre-operatively
Study: 33583740
Drug: Amoxicillin administered
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin administered 48 hours pre-operatively
Study: 33583740
Drug: Amoxicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (250 mg/dose every 8 h x 3 doses beginning 1 h before surgery)
Study: 36772948
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication treatment
Study: 33757937
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter with concurrent oxytocin administration
Study: 36097565
Drug: Integrated rehabilitation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated rehabilitation (combination of TCM and Western conventional rehabilitation methods including acupuncture, repeated transcranial magnetic stimulation, traditional Chinese herbal medicine, and standard care)
Study: 34321316
Drug: SCO-267 (GPR40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCO-267 (GPR40 full agonist)
Study: 34120773
Drug: Dasatinib 140
Normalized name: dasatinib 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 140 mg once daily
Study: 34602349
Drug: methotrexate, vinblastine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles)
Study: 34602349
Drug: cisplatin (mandatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin (mandatory minimum total dose of 270 mg/m2)
Study: 34602349
Drug: cisplatin-based chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin-based chemotherapy (at least 4 cycles)
Study: 34602349
Drug: cisplatin (full
Approvals — FDA: no, EMA: no, PMDA: no
Description: cisplatin (full doses given in 1866 cycles, 88%)
Study: 32723264
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg sublingual melatonin the evening before and 1 hour before surgery
Study: 35686812
Drug: Percutaneous ablation
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous ablation therapy (AT)
Study: 32198638
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel (Group B)
Study: 35963369
Drug: Ivarmacitinib 8
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivarmacitinib 8 mg QD
Study: 35963369
Drug: Ivarmacitinib 4
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivarmacitinib 4 mg BID
Study: 35963369
Drug: Ivarmacitinib 4
Normalized name: Ivarmacitinib
DrugBank: Ivarmacitinib (DB16756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivarmacitinib 4 mg QD
Study: 38214552
Drug: Oral TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TXA
Study: 35920250
Drug: Low-dose magnesium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose magnesium sulfate solution (MSS)
Study: 32070395
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administered at a loading dose of 1 g, followed by 1 g every 8 hours for a maximum of 24 hours, in addition to standard care.
Study: 35859928
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum IL6_0 (≥3.67 pg/mL)
Study: 35859928
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum TNFα_0 (≥14.8 pg/mL)
Study: 32722250
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Probiotic (Saccharomyces cerevisiae CNCM I-3856)
Study: 32722250
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Probiotic (Saccharomyces cerevisiae CNCM I-3856)
Study: 34335740
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard therapy)
Study: 32444035
Drug: Barberry extract
Normalized name: barberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barberry extract (500 mg, 6 capsules daily for 3 months)
Study: 35578351
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (complex intervention to encourage deprescribing antidepressants)
Study: 34541630
Drug: Hormonal oral
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal oral contraceptive
Study: 32661756
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) agonist for 4 months preoperatively (group G)
Study: 32661756
Drug: Gonadotropin-releasing hormone
Normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gonadotropin-releasing hormone (GnRH) agonist
Study: 32661756
Drug: Dienogest (DNG)
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest (DNG) and Gonadotropin-releasing hormone (GnRH) agonist
Study: 35644672
Drug: Double dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dosage of 23-valent pneumococcal polysaccharide vaccine (PPV23) in WLPs
Study: 35644672
Drug: Normal dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dosage of 23-valent pneumococcal polysaccharide vaccine (PPV23) in WLPs
Study: 35644672
Drug: Double dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dosage of pneumococcal vaccines in KTRs
Study: 35644672
Drug: Normal dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal dosage of pneumococcal vaccines in KTRs
Study: 35644672
Drug: Double dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double dosage of pneumococcal vaccines in WLPs
Study: 34184576
Drug: Early lactate-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early lactate-guided treatment
Study: 34516655
Drug: Selenium (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (200 μg) and Vitamin E (400 units) for 3 months
Study: 35656824
Drug: Clopidogrel‐aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel‐aspirin
Study: 35869572
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy for 12 months
Study: 33484896
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Training (HIIT) thrice-weekly for 12 weeks
Study: 33484896
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) daily doses of 12.5 mg for 12 weeks
Study: 35241434
Drug: L-PF Dyspnoea
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PF Dyspnoea score
Study: 35241434
Drug: L-PF Cough
Normalized name: Pediaclear Cough
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PF Cough score
Study: 32151287
Drug: Wild blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wild blueberry (WBB) supplementation (253 mg anthocyanins daily for 4 weeks)
Study: 35988194
Drug: Clarithromycin capsules
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin capsules (Control)
Study: 32918135
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg FA/day
Study: 32918135
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g creatine
Study: 32434399
Drug: Aspirin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin at a dose of 150 mg at bedtime
Study: 33252489
Drug: Intervention (psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (psychosocial counseling, systems navigation, and antiretroviral treatment)
Study: 34627684
Drug: Conventional infertility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional infertility treatment
Study: 33526728
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet treatment with aspirin 100‐160 mg once daily and clopidogrel 75 mg once daily for three months (Group A)
Study: 33526728
Drug: Aspirin 100‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100‐160 mg once daily for three months (Group B)
Study: 33526728
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C) treated according to appropriate treatment guidelines
Study: 34814819
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (DPA and EPA)
Study: 34464231
Drug: Optimal response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Optimal response adaptive design for treatment allocation
Study: 35082514
Drug: Ticagrelor treatment
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor treatment
Study: 37488448
Drug: Cetuximab treatment
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab treatment
Study: 34474433
Drug: CV̇O2 (42.49
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV̇O2 (42.49 ± 3.22 ml·kg−1·min−1)
Study: 34474433
Drug: CV̇O2slow (38.26
Approvals — FDA: no, EMA: no, PMDA: no
Description: CV̇O2slow (38.26 ± 2.43 ml·kg−1·min−1)
Study: 32967775
Drug: Icosapent ethyl
Normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Icosapent ethyl (IPE) 4 g daily (2 g BID with food)
Study: 32967775
Drug: Placebo (paraffin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (paraffin oil 2 g BID with food)
Study: 35849020
Drug: FAMily‐Oriented Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAMily‐Oriented Support (FAMOS) family therapy program, includes seven home-based psychotherapeutic sessions
Study: 34620799
Drug: Aflibercept treatment
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept treatment (intravitreal injections)
Study: 33356580
Drug: Hydrogen-rich water
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich water (HRW); six 30-min ankle baths throughout the first 24 hours post-injury, administered every 4 hours.
Study: 39631042
Drug: Budesonide oral
Normalized name: budesonide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide oral suspension (BOS) 2.0 mg twice daily
Study: 32783280
Drug: Hybrid method
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid method (using loose seeds in combination with stranded seeds)
Study: 36322627
Drug: Immunosuppressive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressive drugs
Study: 34470913
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) supplementation (0.3 g/kg body mass) with warm-up
Study: 35418868
Drug: Drugs for
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for GERD
Study: 33214093
Drug: IVIg (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (400 mg/kg, IV, daily for three days)
Study: 34527921
Drug: Orofacial exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial exercise program twice a day for one month in addition to oral hygiene care advices (Group 1)
Study: 34527921
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene care advices for the first month followed by orofacial exercise program for the next month (Group 2)
Study: 36027955
Drug: Amoxicillin and
Normalized name: omeprazole, amoxicillin and rifabutin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin and clavulanic acid administration
Study: 36027955
Drug: Timing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing of antibiotic administration
Study: 36047047
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation of hydroxychloroquine (200 mg tablet)
Study: 36047047
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation of hydroxychloroquine (200 mg tablet)
Study: 37450351
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Therapy (ET)
Study: 32559027
Drug: Dextroamphetamine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine administration
Study: 34890069
Drug: MSC‐NTF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC‐NTF treatment
Study: 34011040
Drug: Bi Qi
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi Qi Capsules (BQC) in combination with Methotrexate
Study: 33883477
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity (PA) therapy based on intelligent wearable devices for 8 weeks
Study: 33883477
Drug: Internet-based modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based modified behavioral activation (BA) therapy for 8 weeks
Study: 38951007
Drug: Standard Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Oxygen Therapy
Study: 35586186
Drug: Peficitinib 50
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 50 mg single dose
Study: 35586186
Drug: Peficitinib 100
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 100 mg single dose
Study: 35586186
Drug: Peficitinib 150
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib 150 mg single dose
Study: 35586186
Drug: Peficitinib multiple
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib multiple doses (50, 100, 150 mg)
Study: 35586186
Drug: Peficitinib multiple
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib multiple doses (higher dose groups)
Study: 35586186
Drug: Peficitinib multiple
Normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Peficitinib multiple doses (lower dose groups)
Study: 34968124
Drug: Suicide prevention-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suicide prevention-focused group therapy
Study: 34436928
Drug: Veliparib 120
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib 120 mg twice daily with carboplatin and paclitaxel
Study: 34436928
Drug: Veliparib with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veliparib with chemotherapy
Study: 34436928
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with chemotherapy
Study: 36029162
Drug: Prognostic-efficacy-combination design
Normalized name: Designer Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prognostic-efficacy-combination design
Study: 33616557
Drug: ID group
Normalized name: MenQuadfi, polysaccharide tetanus toxoid group ACYW intramuscular solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID group (n = 20) with abutment preparations for inlay retainers (proximal box and occlusal extension)
Study: 33616557
Drug: PB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB group (n = 10) with only proximal box preparations
Study: 34957988
Drug: Standardized treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatment
Study: 33767162
Drug: Low-dose tamoxifen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tamoxifen (5 mg/day)
Study: 32131824
Drug: Personal characteristics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal characteristics of IFs (e.g., flexible, assertive)
Study: 34289884
Drug: Twice-weekly KBA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly KBA training (n = 40)
Study: 34289884
Drug: Thrice-weekly KBA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly KBA training (n = 40)
Study: 32402555
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg monthly
Study: 32402555
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 0.5 mg pro re nata (PRN) after 3 loading doses
Study: 32402555
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 2.0 mg monthly
Study: 32402555
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab 2.0 mg PRN
Study: 34162645
Drug: 12-week open-label
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week open-label placebo treatment
Study: 32213291
Drug: Quetiapine 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quetiapine 12.5 mg every 12 hours
Study: 34166959
Drug: Pharmacist-led educational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led educational intervention on inhalation technique education via demonstration and repetition
Study: 33634858
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (NAT) with imatinib, median duration 6.3 months
Study: 38484209
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (NAT)
Study: 33634858
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (NAT) vs Upfront resection (UR)
Study: 36293748
Drug: ANZANSI intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANZANSI intervention (combination of family economic empowerment and multiple family group family strengthening)
Study: 34622750
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement of 4% ARA
Study: 34622750
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement of ARA (various levels)
Study: 33453192
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy combined with oral medication and exercise
Study: 33453192
Drug: Sham extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham extracorporeal shock wave therapy combined with oral medication and exercise
Study: 35351353
Drug: Online self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online self-help using cognitive-behavioral therapy and positive psychology principles (n = 301)
Study: 34196269
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy plus standardised medical care
Study: 32824061
Drug: Mindfulness treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness treatment (flow meditation)
Study: 33615833
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid infusion
Study: 32779416
Drug: Antibiotics +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics + bee products
Study: 34479631
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of treatment
Study: 33316557
Drug: Carboplatin-based chemotherapy
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based chemotherapy
Study: 32538865
Drug: Weekly ParkinSong
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly ParkinSong
Study: 32538865
Drug: Monthly ParkinSong
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly ParkinSong
Study: 32538865
Drug: Monthly control
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly control
Study: 32538865
Drug: Weekly control
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly control
Study: 34453873
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide (HP) gel with prefilled trays (PT) for 30 minutes
Study: 34453873
Drug: 10% hydrogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% hydrogen peroxide (HP) gel with customized trays (CT) for 30 minutes
Study: 34453873
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) gel with customized trays (CT) for 2 hours
Study: 34453873
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) gel with customized trays (CT) for 8 hours